Literature DB >> 11516944

Antimicrobial susceptibility of community-acquired uropathogens in northern Israel.

R Colodner1, Y Keness, B Chazan, R Raz.   

Abstract

In order to study the trends in resistance to first line antimicrobial agents, the susceptibility patterns of 8338 community urinary isolates collected during 1995 were compared with 6692 isolates from 1999. Our data shows that community-acquired Gram-negative uropathogens remained highly susceptible to ciprofloxacin, cefuroxime and amoxycillin/clavulanate with sensitivities of 94, 89 and 83% respectively. Nitrofurantoin was shown to be suitable (99% susceptibility rate) only for Escherichia coli urinary tract infections. Ampicillin, first generation cephalosporins and sulphamethoxazole/trimethoprim could no longer be considered first line drugs for empirical treatment of clinically evident urinary tract infection because of very high resistant rates. Ampicillin remained a good choice for urinary infections caused by enterococci, 98% of the strains being susceptible. It was found that 1.25% of the Gram-negative uropathogens isolated during 1999 were extended spectrum beta-lactamase producers which suggests that this plasmid-encoded trait is finding its way into the community.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516944     DOI: 10.1016/s0924-8579(01)00368-5

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  11 in total

1.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

2.  Microbial Etiology and Antimicrobial Susceptibility of Bactria Implicated in Urinary Tract Infection in Tehran, Iran.

Authors:  Zohreh Nozarian; Alireza Abdollahi
Journal:  Iran J Pathol       Date:  2015

3.  Extended-spectrum β-lactamase (ESBL) in Omani Children: Study of prevalence, risk factors and clinical outcomes at Sultan Qaboos University Hospital, Sultanate of Oman.

Authors:  Zakariya Al Muharrmi; Akbar M Rafay; Abdullah Balkhair; Salem Al-Tamemi; Ali Al Mawali; Hilal Al Sadiri
Journal:  Sultan Qaboos Univ Med J       Date:  2008-07

4.  What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study.

Authors:  T Y Ti; G Kumarasinghe; M B Taylor; S L Tan; A Ee; C Chua; A Low
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-22       Impact factor: 3.267

Review 5.  Plasmid-mediated quinolone resistance: a multifaceted threat.

Authors:  Jacob Strahilevitz; George A Jacoby; David C Hooper; Ari Robicsek
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

6.  Clinico-microbiological profile of urinary tract infection in south India.

Authors:  M Eshwarappa; R Dosegowda; I Vrithmani Aprameya; M W Khan; P Shiva Kumar; P Kempegowda
Journal:  Indian J Nephrol       Date:  2011-01

7.  Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India.

Authors:  Mohammed Akram; Mohammed Shahid; Asad U Khan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-03-23       Impact factor: 3.944

8.  Antibiotic prophylaxis with intravenous ceftriaxone and fluoroquinolone reduces infectious complications after transrectal ultrasound-guided prostatic biopsy.

Authors:  Chunwoo Lee; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Myung-Soo Choo; Hanjong Ahn; Tai Young Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2015-06-02

9.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

10.  Antibacterial resistance, Wayampis Amerindians, French Guyana.

Authors:  Karine Grenet; Didier Guillemot; Vincent Jarlier; Brigitte Moreau; Stéphane Dubourdieu; Raymond Ruimy; Laurence Armand-Lefevre; Pierre Bau; Antoine Andremont
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.